Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
08:21pm, Monday, 10'th Nov 2025
BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wad
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
10:41am, Saturday, 08'th Nov 2025
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared t
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
01:00pm, Friday, 07'th Nov 2025
Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enfor
Teacher Retirement System of Texas Grows Position in BridgeBio Pharma, Inc. $BBIO
03:45am, Wednesday, 05'th Nov 2025
Teacher Retirement System of Texas grew its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 8.3% during the undefined quarter, according to the company in its most recent filing with the Securities
BridgeBio to Participate in November Investor Conferences
07:30am, Tuesday, 04'th Nov 2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts
02:33pm, Friday, 31'st Oct 2025
BBIO's Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer's Tafamidis and Alnylam's Amvuttra. Its US uptake keeps
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
10:56pm, Wednesday, 29'th Oct 2025
BridgeBio Pharma, Inc. ( BBIO ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
06:16pm, Wednesday, 29'th Oct 2025
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.86 per share a year ago.
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
04:01pm, Wednesday, 29'th Oct 2025
PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
12:06pm, Wednesday, 29'th Oct 2025
BridgeBio Pharma, Inc. ( BBIO ) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study October 29, 2025 8:00 AM EDT Company Participants Neil Kumar - Co-Founder, CEO & Director Ana
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
07:00am, Wednesday, 29'th Oct 2025
A second positive "domino" fell for BridgeBio stock on Wednesday after the company reported promising results for a genetic disease drug.
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
07:00am, Wednesday, 29'th Oct 2025
- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered enca
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
04:01pm, Tuesday, 28'th Oct 2025
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
10:16am, Tuesday, 28'th Oct 2025
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre
